News

Preclinical studies demonstrated that daily oral administration of 2ME2 resulted in a dose-dependent decrease in inflammation and tissue destruction in two distinct animal models of rheumatoid arthritis. Treatment

The two proprietary compounds are NAP, from which Allon has derived its first and second products AL-108 and AL-208, and ADNF-9, from which the company has derived product

The collaboration combines the peptide production capabilities of Biocon with the proprietary oral peptide delivery technology of Nobex. The company’s plan to advance the oral human brain-type natriuretic

Neuroscientists from the University at Buffalo have shown that rotenone, an environmental toxin linked specifically to Parkinson’s disease, damages dopamine producing neurons critical to body movement and muscle

ML-133 and LT-253 are part of the ML-series, which is a group of novel low molecular weight compounds that shows significant anti-proliferative activity against many human cancer cell

The trial which tests the effects of the drug in patients with secondary progressive multiple sclerosis (SPMS) is currently enrolling patients in Canada and the UK. Up to

This research at Wake Forest provided the basis for conducting the phase II sleep deprivation study in humans, which confirmed CX717 improved wakefulness, memory, cognition and attention without

In the trial the drug, discovered by Pharmasset and licensed to Incyte, exceeded the contractually-defined goal of a 90% reduction in HIV viral load in the bloodstream. Results

The researchers produced the change in the mice by manipulating a precise area of the animals’ amygdala, a region of the brain critical to emotional stress and learning.